Abstract #1413498: Whole Body Digital Twin Technology for Remission of T2DM and Normalization of Glycemic and Fatty Liver Parameters: 1 Year Intent to Treat Analysis of the Prospective Randomized Controlled Clinical Trial

Abstract

Twin Precision Treatment (TPT) is a novel Whole-Body Digital Twin (WBDT) enabled precision nutrition for reversing diabetes, that uses AI and the Internet of Things, to integrate multidimensional data, from non-invasive sensors, to give precision nutrition and health recommendations via the TPT app and by coaches. We conducted a prospective randomized trial to compare the changes in the glycemic metrics and the fatty liver parameters. The Intent to Treat (ITT) analysis among 233 people with T2DM who underwent WBDT was done at one year. 84 T2DM were provided the standard of care (SC). Remission was defined as an A1C level <6.5% for ≥ six months without diabetes medication use for at least 90 days. Normal values were: BMI <25kg/m2, HbA1c <6.5%, FPG <126 mg/dl, HOMA2-IR <1.22, NAFLD Liver Fat Score (NAFLD-LFS) <-0.64, Fatty Liver Score (FLS) <23, Framingham Steatosis Index (FSI) <23. Of the 233 people with T2DM, 209 subjects completed more than six months of WBDT. 72.7% (152/209) sustained remission at one year. The mean age, duration of diabetes, were 43 years (±9.5, range 17 to 69) and 3.4 years (±2.7, range 0.1 to 8). WBDT (n=233) intervention led to a significant number (p<0.0001) of subjects achieving the normalized values from baseline and at 1 year, for BMI (76 to 133), HbA1c (16 to 184), FPG (57 to 181), HOMA2-IR (48 to 130), NAFLD-LFS (26 to 149), FLI (30 to 120), FSI (29 to 135). ALT (68 to 140). One-year improvement in HbA1C was significantly better for WBDT than SC -3.0 (±1.8) vs. -0.2 (±1.2); p<0.001. Our ITT analysis shows that WBDT enables a high rate of remission of T2DM with a durable benefit, beyond six months for the glycemic control. There is a significant increase in the number of people who achieve the normalised biochemical and clinical values, for glycemic and fatty liver indices, while they remain in T2DM remission, at one year